Bridging Bench to Bedside: An Integrated Model-Informed Strategy to Reduce ADC Attrition

Author: Hariprasad Reddy Gadi

Antibody-drug conjugates combine the specificity of monoclonal antibodies with the potency of cytotoxic payloads, offering significant promise in oncology. However, despite recent clinical successes, many ADC candidates still fail during development due to fragmented workflows and disconnected decision-making.

This whitepaper presents a comprehensive model-informed strategy that integrates biology, chemistry, pharmacokinetics (PK), pharmacodynamics (PD), bioanalysis, and clinical development into a unified framework. By connecting data across every stage of development, organizations can better predict clinical outcomes, optimize dosing strategies, and reduce costly late-stage failures.

What you’ll learn

After downloading this whitepaper, you’ll discover:

• Why promising ADC candidates continue to fail during clinical development
• How target biology, linker chemistry, DAR, and payload selection influence therapeutic success
• The importance of integrated PK/PD and PBPK modeling in ADC optimization
• Best practices for multi-analyte bioanalysis and metabolite safety assessment
• How translational models improve confidence from preclinical studies to first-in-human trials
• Personalized dosing strategies using model-informed precision dosing (MIPD)
• A practical integrated framework that connects experimental data with clinical decision-making throughout ADC development.

Download this whitepaper to explore practical strategies for reducing development risk, improving translational confidence, and accelerating successful ADC programs.